Palvella Therapeutics (FRA:PI6) Marketable Securities: €47.97 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:PI6 Palvella Therapeutics Inc FRA:PI6
20 GF Score
Price €125.00
! 2 Warning Signs
View Full Analysis

What is Palvella Therapeutics Marketable Securities?

Palvella Therapeutics FRA:PI6 +1.63% 20 Marketable Securities is €47.97 Mil as of Mar. 2026. GuruFocus rates FRA:PI6 with a GF Score™ of 20/100. The stock has 2 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Palvella Therapeutics's Marketable Securities for the quarter that ended in Mar. 2026 was €47.97 Mil.

Palvella Therapeutics  (FRA:PI6) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Palvella Therapeutics Marketable Securities Related Terms

Palvella Therapeutics Marketable Securities Historical Data

* Premium members only.

The historical data trend for Palvella Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Palvella Therapeutics Marketable Securities Chart

Palvella Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Marketable Securities
0.00 0.00 0.00 0.00

Palvella Therapeutics Quarterly Data
Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 47.97
FRA:PI6
20GF Score
Palvella Therapeutics Inc FRA:PI6
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Palvella Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of €47.97 Mil mean?
Palvella Therapeutics (FRA:PI6) has a Marketable Securities of €47.97 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Palvella Therapeutics and its competitors.
Is Palvella Therapeutics' Marketable Securities too high?
Palvella Therapeutics' current Marketable Securities is €47.97 Mil. Overall, Palvella Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Palvella Therapeutics' Marketable Securities compare to GENB and NKTR?
Palvella Therapeutics' Marketable Securities of €47.97 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Palvella Therapeutics and its competitors. Palvella Therapeutics's current Marketable Securities is €47.97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Palvella Therapeutics stock overvalued right now?
Palvella Therapeutics (FRA:PI6) has a current Marketable Securities of €47.97 Mil. The current Marketable Securities is €47.97 Mil. Palvella Therapeutics' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Palvella Therapeutics (FRA:PI6), the current Marketable Securities is €47.97 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Palvella Therapeutics Business Description

Other Exchanges PVLA:USA
Address 353 W. Lancaster Avenue, Suite 200, Wayne, PA, USA, 19087
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
20GF Score

Get the complete analysis for FRA:PI6

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€125.00
Price